These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38827177)

  • 1. PARP inhibitors in prostate cancers, is it time for combinations?
    Teyssonneau D; Dariane C; Barret E; Beauval JB; Brureau L; Fiard G; Fromont G; Créhange G; Gauthé M; Ruffion A; Renard-Penna R; Mathieu R; Sargos P; Rouprêt M; Ploussard G; Roubaud G
    Ther Adv Med Oncol; 2024; 16():17588359241242959. PubMed ID: 38827177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
    Teyssonneau D; Thiery-Vuillemin A; Dariane C; Barret E; Beauval JB; Brureau L; Créhange G; Fiard G; Fromont G; Gauthé M; Ruffion A; Renard-Penna R; Mathieu R; Sargos P; Rouprêt M; Ploussard G; Roubaud G; On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35330059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of PARP inhibitors in advanced prostate cancer.
    Bourlon MT; Valdez P; Castro E
    Ther Adv Med Oncol; 2024; 16():17588359231221337. PubMed ID: 38205078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    Adashek JJ; Jain RK; Zhang J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    Ziadeh T; Kourie HR
    Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
    Maughan BL; Antonarakis ES
    Expert Opin Pharmacother; 2021 Aug; 22(12):1625-1632. PubMed ID: 33827356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors in metastatic prostate cancer.
    Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
    Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N
    Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
    Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
    Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1293-1304. PubMed ID: 36285641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.
    McFarland TR; Kessel A; Swami U; Agarwal N
    Am J Transl Res; 2021; 13(7):7427-7439. PubMed ID: 34377227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Jang A; Sartor O; Barata PC; Paller CJ
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.